TY - JOUR
T1 - HDL cholesterol performance using an ultracentrifugation reference measurement procedure and the designated comparison method
AU - Nakamura, Masakazu
AU - Yokoyama, Shinji
AU - Kayamori, Yuzo
AU - Iso, Hiroyasu
AU - Kitamura, Akihiko
AU - Okamura, Tomonori
AU - Kiyama, Masahiko
AU - Noda, Hiroyuki
AU - Nishimura, Kunihiro
AU - Nakai, Michikazu
AU - Koyama, Isao
AU - Dasti, Mahnaz
AU - Vesper, Hubert W.
AU - Teramoto, Tamio
AU - Miyamoto, Yoshihiro
N1 - Funding Information:
This work was supported by a Health and Labour Sciences Research Grant , Japan (Comprehensive Research on Lyfestyle-Related Diseases Including Cardiovascular Diseases and Daibetes Mellitus) from the Minustry of Health, Labour, and Welfare of Japan . The authors would like to thank Dr. Katsuyuki Nakajima and Dr. Ikunosuke Sakurabayashi for their valuable comments and discussion, and Ms. Yukari Ichikawa for her excellent help in providing the references and manuscript.
Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2015/1/5
Y1 - 2015/1/5
N2 - Background: Accurate high-density lipoprotein cholesterol (HDL-C) measurements are important for management of cardiovascular diseases. The US Centers for Disease Control and Prevention (CDC) and Cholesterol Reference Method Laboratory Network (CRMLN) perform ultracentrifugation (UC) reference measurement procedure (RMP) to value assign HDL-C. Japanese CRMLN laboratory (Osaka) concurrently runs UC procedure and the designated comparison method (DCM). Osaka performance of UC and DCM was examined and compared with CDC RMP. Methods: CDC RMP involved UC, heparin-MnCl2 precipitation, and cholesterol analysis. CRMLN DCM for samples containing <200mg/dl triglycerides involved 50-kDa dextran sulfate-MgCl2 precipitation and cholesterol determination. Results: HDL-C regression equations obtained with CDC (x) and Osaka (y) were y=0.992x+0.542 (R2=0.996) for Osaka UC and y=1.004x-0.181 (R2=0.998) for DCM. Pass rates within ±1mg/dl of the CDC target value were 91.9 and 92.1% for Osaka UC and DCM, respectively. Biases at 40mg/dl HDL-C were +0.22 and -0.02mg/dl for Osaka UC and DCM, respectively. Conclusions: Osaka UC and DCM were highly accurate, precise, and stable for many years, assisting manufacturers to calibrate products for clinical laboratories to accurately measure HDL-C for patients, calculate non-HDL-C, and estimate low-density lipoprotein cholesterol with the Friedewald equation.
AB - Background: Accurate high-density lipoprotein cholesterol (HDL-C) measurements are important for management of cardiovascular diseases. The US Centers for Disease Control and Prevention (CDC) and Cholesterol Reference Method Laboratory Network (CRMLN) perform ultracentrifugation (UC) reference measurement procedure (RMP) to value assign HDL-C. Japanese CRMLN laboratory (Osaka) concurrently runs UC procedure and the designated comparison method (DCM). Osaka performance of UC and DCM was examined and compared with CDC RMP. Methods: CDC RMP involved UC, heparin-MnCl2 precipitation, and cholesterol analysis. CRMLN DCM for samples containing <200mg/dl triglycerides involved 50-kDa dextran sulfate-MgCl2 precipitation and cholesterol determination. Results: HDL-C regression equations obtained with CDC (x) and Osaka (y) were y=0.992x+0.542 (R2=0.996) for Osaka UC and y=1.004x-0.181 (R2=0.998) for DCM. Pass rates within ±1mg/dl of the CDC target value were 91.9 and 92.1% for Osaka UC and DCM, respectively. Biases at 40mg/dl HDL-C were +0.22 and -0.02mg/dl for Osaka UC and DCM, respectively. Conclusions: Osaka UC and DCM were highly accurate, precise, and stable for many years, assisting manufacturers to calibrate products for clinical laboratories to accurately measure HDL-C for patients, calculate non-HDL-C, and estimate low-density lipoprotein cholesterol with the Friedewald equation.
UR - http://www.scopus.com/inward/record.url?scp=84909952744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84909952744&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2014.10.039
DO - 10.1016/j.cca.2014.10.039
M3 - Article
C2 - 25444739
AN - SCOPUS:84909952744
SN - 0009-8981
VL - 439
SP - 185
EP - 190
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -